Drug Trial Radar · NCT05271292
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Last checked: Nov 19, 2026Latest source record: Jul 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 26, 2022
Primary completion
Mar 2025
Study completion May 2025
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Conditions
- Small Cell Lung Cancer
- Advanced Solid Malignant Tumor
Interventions
ChiauranibDrug
Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and other safety parametersTime frame: Until 30 days after a patient takes the last dose of the study drug
- Incidence and characteristics of DLTsTime frame: 34 days
- MTD and recommended Phase 2 dose (RP2D)Time frame: 34 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
California Cancer Associates-Encintas
Encinitas, California · Recruiting
Providence/St. Joe Cancer Institute/Crosson Cancer Institute
Fullerton, California · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Dana Farber Cancer Institue
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
OU Health
Oklahoma City, Oklahoma · Recruiting
Sarah Cannon Research Center
Nashville, Tennessee · Recruiting
North Houston Cancer Clinics
Huntsville, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.